Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HGF monoclonal antibody YYB101

A humanized monoclonal antibody directed against human hepatocyte growth factor (HGF), with potential antineoplastic activity. Upon administration, anti-HGF monoclonal antibody YYB101 targets and binds to HGF, preventing the binding of HGF to the HGF receptor c-Met and the activation of the c-Met signaling pathway. This may result in cell death in c-Met-expressing tumor cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	anti-hepatocyte growth factor monoclonal antibody YYB101
Code name:	YYB 101 YYB-101 YYB101

anti-HGF monoclonal antibody YYB101

Search NCI's Drug Dictionary